Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility (PDMRs) under the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding internal plan transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan, resulting in an increase in the notional allocation of American Depositary Shares (ADSs) on March 15, 2013, at a price of $45.30 per ADS.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly addresses compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: March 15, 2013 (Notification date: March 18, 2013).
- Transaction Type: Increase in notional allocation of ADSs due to plan revaluation.
- Price per ADS: $45.30.
- Directors/PDMRs Involved: Dr. M M Slaoui (20 ADSs) and Dr. K Slaoui (30 ADSs, Connected Person).
- Financial Data: No financial performance metrics are included in this specific filing.